Introduction
Chronic renal failure (CRF) is characterised by a progressive loss of kidney function. The decrease of the glomerular filtration results from the irreversible loss of a large number of functional nephrons (1) and it is quantified by the glomerular filtration rate (GFR). At early stages (Stages 1 and 2), kidney damage is generally clinically asymptomatic; most of the kidney functions are preserved, but the risk for progressive disease is increased significantly. As renal disease worsens, kidney functions begin to deteriorate (Stages 3 and 4). Eventually, end-stage renal failure (Stage 5) ensues, and kidney replacement or dialysis therapies are required (2) .
CRF patients have been reported as a group showing genomic instability. This instability is manifested by using several biomarkers, including DNA repair defects; thus, reduction of the repair ability in cells from pre-dialysis patients irradiated with ultraviolet (UV) light has been reported (3, 4) .
Genomic instability has also been detected in patients submitted to dialysis therapy (5); but, surprisingly, repair was increased in dialysis patients in early stages of dialysis, although it declined in those patients submitted to dialysis for .120 months (6) . The presence of genomic instability and high levels of genetic damage in CRF has been associated with the high incidence of both cardiovascular pathologies and cancer observed in this group of patients (7) (8) (9) (10) .
As a consequence of genomic instability, increased levels of genetic damage have also been observed in CRF patients; measured using different biomarkers such as sister chromatid exchanges (11) , comet assay (12, 13) and micronuclei (MN) (14, 15) , all of them have been reported to be increased in CRF patients [undergoing or not haemodialysis (HD)].
The frequency of MN in peripheral blood lymphocytes is considered a sensitive indicator of exposure to exogenous or endogenous sources of genetic damage, and it is considered a good surrogate biomarker of cancer risk (16, 17) . MN are defined as small chromatin bodies appearing in the cytoplasm by the condensation of acentric chromosome fragments or by whole chromosomes, lagging behind the cell division. Thus, it is the only biomarker that allows the simultaneous evaluation of both clastogenic and aneugenic effects on the whole genome.
Although most of the studies on the levels of genetic damage in CRF patients have been conducted in dialytic patients, and with low number of individuals, it is not completely concluded if increased levels of genetic damage are a general characteristic of CRF patients, independently of their GFR state. Our study aims to generate data addressed to answer this question. Thus, the levels of genetic damage in peripheral blood lymphocytes of a large group of CRF patients have been determined by using the MN assay. A total of 201 patients (103 CRF patients in different stages and 98 HD patients), together with 57 controls, have been evaluated to determine whether the levels of chromosome damage are linked to the severity of the pathology.
Materials and methods

Samples
The study was carried out in a total of 258 Caucasian adults, 201 CRF patients and 57 controls. From the CRF patients, 98 were included in a programme of HD treatment for an average period of 42.05 months (range 1-259 months) and the remaining 103 were patients in different stages (2-5) of CRF. The characteristics of all patients are indicated in Table I , and all of them were recruited at the Puigvert Foundation, Barcelona.
All study participants completed an interviewer-administered questionnaire in which information concerning their smoking habit, alcohol intake, occupational and other exposure histories, as well as family history of cancer, was requested. After the informed consent was obtained, biological samples were collected under protocols approved by the Ethics Committee of the Puigvert Foundation.
Evaluation of renal function
We measured serum creatinine concentration by using IDMS (isotope dilution mass-spectrometry) method. We calculated the estimated GFR from serum creatinine by using the modified 4-variable version of the Modification of Diet in Renal Disease formula (18) .
Lymphocyte culture and MN assay Blood samples were obtained from each subject by venipuncture using heparinised vacutainers and were sent directly to the laboratory of the Mutagenesis Group at the Autonomous University of Barcelona in Bellaterra (Spain). Blood was processed no more than 3 h after it was drawn at the hospital. Lymphocyte cultures were set up by adding 0.5 ml of whole blood into 4.5 ml of RPMI 1640 medium supplemented with 15% of heat-inactivated foetal calf serum, 1% of antibiotics (penicillin and streptomycin) and 1% of L-glutamine (all provided by Gibco Life Technologies, Paisley, UK). Lymphocytes were stimulated by 1% of phytohaemagglutinin (Gibco) at 37°C. After 44 h, 6 lg/ml of cytochalasin B (Cyt-B; Sigma, St Louis, MO, USA) were added to the culture to arrest cytokinesis. At 72 h of incubation, cultures were harvested by centrifugation at 120 g for 8 min. Next, blood cultures were washed once in RPMI 1640 medium followed by a mild hypotonic treatment (2-3 min in 0.075 M KCl at 4°C). Cells were centrifuged and fixed in a methanol:acetic acid (3:1 v/v) solution. Two or more slides were coded and stained with 10% of Giemsa (Merck, Darmstadt, Germany) in phosphate buffer (pH 6.8) for 10 min.
To determine the frequency of binucleated cells with micronuclei (BNMN) and the total number of MN, a total of 1000 binucleated cells with wellpreserved cytoplasm (500 per replicate), for each subject, were blind scored on coded slides. In addition, a total of 500 lymphocytes were scored to determine the percentage of cells with one, two or more nuclei and the cytokinesis-block proliferation index (CBPI) was calculated (19) .
Statistical analyses
Statistical computations were performed by using the SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). A multiple regression analysis was carried out to evaluate the possible effects of the confounding factors considered in this study Differences between group GFR . 30-90 ml/min and GFR, 30 ml/min. b Differences between group GFR . 30-90 ml/min and CRF/HD. t-test differences, regarding control group: *P , 0.05, **P , 0.01, ***P , 0.00. 
Results
Some general characteristics of the population under study are shown in Table I . Men are overrepresented among these patients, reflecting the higher incidence of CRF on this gender; consequently in controls, a similar proportion of men were selected. The average age for dialysis patients is 62. Table I also shows some parameters from the blood chemistry data. As expected in CRF patients, increased values were observed for several markers (polymerase chain reaction, homocysteine, folate, etc). Table II shows the genetic damage observed in both patients and controls. The observed BNMN values, as well as the total frequency of MN are presented. In addition, the CBPI index, as measure of cytotoxicity is also indicated. From this table, it is clear that CRF patients show significant increases in the levels of genetic damage. When CRF patients are classified as not on HD and submitted to HD, higher frequencies of BNMN are observed in those patients undergoing HD.
To determine the role of the GFR parameter on the BNMN frequency, the overall population (controls þ CRF patients) was classified according to the GFR stage. As it can be seen in Figure 1 , the BNMN frequency increases when the GFR stage increases. This relationship is also observed in Figure 2 , where a significant association (P 5 0.002) is observed between BNMN frequency and GFR values. Complementary to these data, Figure 3 shows that the frequency of BNMN directly increases with the serum creatinine levels (P 5 0.017).
The multiple regression analysis shows that several confounding factors influence significantly on the BNMN frequency, as gender (P 5 0.0001), age (P 5 0.032) and cancer (P 5 0.056), as well as dyslipidemia (P 5 0.007) (Table III) .
Since there are an important number of patients with cancer, we have spliced the patients, according to the presence/absence of cancer (Table IV) . No differences were observed in total MN or BNMN for those patients from CRF stages 2-3 and, although CRF patients with cancer from Stages 4-5 showed higher values of total MN and BNMN, these differences did not attain statistical differences, mainly due to the large variability observed in MN values. For CRF patients under haemodialysis, those with previous diagnostic of cancer present significant increases in the MN frequencies (P , 0.05). Nevertheless, in those CRF patients without cancer diagnosis, the frequency of MN correlates positively with the progression of the pathology, showing significant increases in the frequency of MN, both total and BNMN. Unfortunately, we have no data on the antitumoral treatments received by the patients to look for causal effects.
Discussion
A general finding of this study is the confirmation that CRF patients exhibit increased levels of genetic damage, as measured by the MN assay. The relevance of this biomarker is that MNs represent fixed genetic damage resulting from both 
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aneugenic and clastogenic mechanisms (20) . In addition, our genotoxicity data showed to be positively associated with the progression of the kidney disease, as evaluated by the GFR.
Increases in the frequency of MNs have been considered good indicators of genetic instability and, for this reason, MNs have been proposed as a surrogated biomarker of cancer risk (17) . It must be recalled that this association with risk has been reported at population level, not at individual level. Individual damage values over the standard background would indicate a genetic predisposition, mainly due to the inability to adequately repair DNA lesions or the chronic exposure to genotoxic agents. In CRF patients, genetic instability has been already characterised as a decreased ability to repair DNA lesions; thus, DNA repair was reduced in peripheral blood lymphocytes of CRF patients after in vitro UV or c-irradiation exposure (3,4,6,21) . The presence of genomic instability in CRF patients has also been detected as increases of a defined deletion in the mitochondrial DNA from hair follicles (22) . This biomarker is considered useful since human mitochondrial DNA is much more susceptible to damage, due to the lack of proofreading and poor DNA repair ability (23) . Genomic instability has also been associated with the greater telomere shortening observed in uraemic patients (24) . When telomeres become critically short, chromosome ends are unprotected and chromosome rearrangements appear resulting from the extensive chromosome fusion; this chromosome instability has been associated to cancer development (25) . DNA damage is related with the development of cancer, as it was demonstrated in the pioneer work of Hagmar et al. (26) for the general population. This association has also been demonstrated for the incidence of cardiovascular pathologies in the general population (27) , which is supported for the monoclonal origin of cells from human atherosclerotic plaques in the general population (28) .
The link between genetic instability, genetic damage, cancer and cardiovascular pathologies is evidenced in end-stage renal disease patients, where the relative risk of cancer and cardiovascular disease is enhanced (29) . Our study confirms this association because 21% of our patients have tumours and 51% present an increased risk of cardiovascular disease.
In the literature, there are only seven previous studies using the MN assay in peripheral blood lymphocytes of CRF patients. All of them show increased MN levels in patients, although the number of patients included in these studies is very low (ranging from 12 to 38) (14, 15, (30) (31) (32) (33) (34) . The low number of patients did not allow stratifying them according to the different stages of the pathology. This is one of the positive aspects of our work since our large population (201 patients) has made possible to identify worsening increases in the levels of genetic damage with the worsening of the pathology. Our results also show that genomic damage is associated to creatinine levels, which would confirm the association between the degree of renal failure, and its progression, with genomic damage. The fact that the asymptomatic stage (Stage 2) does show increased MN frequencies over controls (GFR . 90 ml/min/ 1.73 m 2 ) would indicate the existence of a genetic predisposition in these patients. This would be confirmed by the higher values observed in Stage 3 patients, when the pathology starts to be symptomatic. Nevertheless, the levels of genomic damage increased as the kidney function became impaired (Stages 4 and 5), which would indicate that part of the genotoxic effects observed have arisen with the progressive loss of kidney function. The highest level of genotoxicity was found in the HD group, where the uraemic state parallels with the bioincompatibility reactions caused by the technique itself (membranes, dialysate, etc.).
Moreover, the graded association between increased MN frequencies and reduced estimated GFR, with genotoxic damage starting at early stages of the kidney disease, let us assume that genetic predisposition associated to a progressive uraemic toxicity is involved in the highest co-morbidity of CRF patients.
Taken together, our findings suggest that MN frequencies could be a reliable biomarker for cancer and cardiovascular disease, as well as a biomarker able to capture patients at preclinical disease that are at greater risk for progression to clinical CRF.
Several endogenous processes have been postulated to occur in CRF patients, being oxidative stress one of the most established. It has been shown that in CRF patients oxidative stress levels are higher than in healthy subjects, and in patients under HD treatment, it is higher than in patients with less advanced stages of CRF. This has been shown measuring the levels of malondialdehyde and oxidative resistance in plasma (35) , and using the comet assay complemented with endoIII and formamidopyrimidine-DNA-glycosylase enzymes (36) . This has been attributed to several causes as uraemia (37) and reduced antioxidant capacity (38) . In addition, various advanced glycation end products and reactive carbonyl compounds, which are markedly enhanced in end-stage renal failure (39) , are also known to induce oxidative stress (40, 41) . A limitation of our study is to be cross-sectional in nature and not a prospective study. It would be very interesting to assess the progress of DNA damage in a long-term follow up study.
As a conclusion, we have shown that CRF patients present increased levels of genetic damage, measured by the MN assay. The fact that genetic damage is already present in the very early stages of the renal failure progression seems to indicate a genetic predisposition in CRF patients. Nevertheless, the following increases in genetic damage levels when renal function decrease would indicate that part of this damage can be attributed to the uraemic state itself. It would be interesting to know if other factors, such as individual genetic characteristics, can modulate the genomic damage observed in CRF patients.
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